Cargando…
Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
OBJECTIVE: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482586/ https://www.ncbi.nlm.nih.gov/pubmed/37170726 http://dx.doi.org/10.3802/jgo.2023.34.e60 |
_version_ | 1785102203117109248 |
---|---|
author | Kotaka, Saki Kondo, Eiji Kawai, Yosuke Okamoto, Kota Kishigami, Yasuyuki Yamawaki, Takaharu Nagao, Kenji Hirata, Toru Suzuki, Shiro |
author_facet | Kotaka, Saki Kondo, Eiji Kawai, Yosuke Okamoto, Kota Kishigami, Yasuyuki Yamawaki, Takaharu Nagao, Kenji Hirata, Toru Suzuki, Shiro |
author_sort | Kotaka, Saki |
collection | PubMed |
description | OBJECTIVE: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribution of the platinum-free interval to the efficacy of subsequent chemotherapy for advanced cervical cancer. METHODS: We retrospectively identified 115 patients with metastatic, recurrent, or persistent cervical cancer treated with platinum-paclitaxel chemotherapy plus bevacizumab at 7 institutions between 2015 and 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients who received bevacizumab maintenance therapy and those who did not. We also analyzed the adverse events associated with bevacizumab and survival time from the start of subsequent chemotherapy in both groups. RESULTS: Following platinum-paclitaxel plus bevacizumab chemotherapy, 34 patients received bevacizumab maintenance therapy and 81 patients did not. Of the 115 patients, 56 received chemotherapy for subsequent relapse. Although bevacizumab maintenance therapy prolonged PFS (median of 16.0 months vs. 9.0 months, p=0.041), significant differences were not observed in OS (p=0.374). Furthermore, bevacizumab maintenance therapy did not prolong OS and PFS after the start of subsequent chemotherapy (p=0.663 and p=0.136, respectively). Bevacizumab maintenance therapy significantly increased hypertension (p=0.035) and proteinuria (p=0.005) but did not cause complications leading to death. CONCLUSION: Bevacizumab single-maintenance therapy for advanced cervical cancer can be considered in selected cases, such as those with acceptable bevacizumab-related side effects. The outcomes of our study will likely contribute to decision-making regarding practical treatment strategies. |
format | Online Article Text |
id | pubmed-10482586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-104825862023-09-08 Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer Kotaka, Saki Kondo, Eiji Kawai, Yosuke Okamoto, Kota Kishigami, Yasuyuki Yamawaki, Takaharu Nagao, Kenji Hirata, Toru Suzuki, Shiro J Gynecol Oncol Original Article OBJECTIVE: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribution of the platinum-free interval to the efficacy of subsequent chemotherapy for advanced cervical cancer. METHODS: We retrospectively identified 115 patients with metastatic, recurrent, or persistent cervical cancer treated with platinum-paclitaxel chemotherapy plus bevacizumab at 7 institutions between 2015 and 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients who received bevacizumab maintenance therapy and those who did not. We also analyzed the adverse events associated with bevacizumab and survival time from the start of subsequent chemotherapy in both groups. RESULTS: Following platinum-paclitaxel plus bevacizumab chemotherapy, 34 patients received bevacizumab maintenance therapy and 81 patients did not. Of the 115 patients, 56 received chemotherapy for subsequent relapse. Although bevacizumab maintenance therapy prolonged PFS (median of 16.0 months vs. 9.0 months, p=0.041), significant differences were not observed in OS (p=0.374). Furthermore, bevacizumab maintenance therapy did not prolong OS and PFS after the start of subsequent chemotherapy (p=0.663 and p=0.136, respectively). Bevacizumab maintenance therapy significantly increased hypertension (p=0.035) and proteinuria (p=0.005) but did not cause complications leading to death. CONCLUSION: Bevacizumab single-maintenance therapy for advanced cervical cancer can be considered in selected cases, such as those with acceptable bevacizumab-related side effects. The outcomes of our study will likely contribute to decision-making regarding practical treatment strategies. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2023-04-28 /pmc/articles/PMC10482586/ /pubmed/37170726 http://dx.doi.org/10.3802/jgo.2023.34.e60 Text en © 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kotaka, Saki Kondo, Eiji Kawai, Yosuke Okamoto, Kota Kishigami, Yasuyuki Yamawaki, Takaharu Nagao, Kenji Hirata, Toru Suzuki, Shiro Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
title | Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
title_full | Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
title_fullStr | Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
title_full_unstemmed | Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
title_short | Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
title_sort | real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482586/ https://www.ncbi.nlm.nih.gov/pubmed/37170726 http://dx.doi.org/10.3802/jgo.2023.34.e60 |
work_keys_str_mv | AT kotakasaki realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT kondoeiji realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT kawaiyosuke realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT okamotokota realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT kishigamiyasuyuki realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT yamawakitakaharu realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT nagaokenji realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT hiratatoru realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer AT suzukishiro realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer |